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Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296S290Methods: OA patients were treated with CS (800 mg/day) or paracetamol
(4 g/day) for 6 month. Clinical examinationwas performed at baseline, and
after 1.5, 6 and 9 months of treatment, with collection of plasma and
synovial ﬂuid. The clinical examination included measurement of the
overﬂow, hypertrophy and vascularisation of the synovia as well as func-
tional study of the articulation (with Lequesne and EVA index). The levels
of CXCL16, fractalkine/CX3CL1, MCP-1/CCL-2, RANTES/CCL5 and GRO-a/
CXCL1 were determined by ELISA in the plasma and synovial samples
collected. The statistical analysis was performed with SPSS package. We
performed two different analyses. In the ﬁrst one, we studied the differ-
ence between the levels of the chemokine between each time and the
baseline. We performed this analysis in separate with the paracetamol
group and chondroitin one. For this comparison we used a non parametric
test (Wilcoxon 2 related samples test). We performed a second analysis in
order to analyze if there were differences in the chemokine levels over
time, depending on the treatment received. For this analysis an indepen-
dent sample t-test was performed.
Results: Improvements in the clinical signs of inﬂammationwere detected
after 6-9 months after CS treatment of OA patients. The comparison of the
levels of each chemokine at the different times studied versus the baseline,
indicated us that these effects were accompanied by a signiﬁcant reduction
in the synovial levels of MCP-1 at 6 month (p¼0.05), whereas in the par-
acetamol group there was a signiﬁcant increased level of RANTES
(p¼0.035). In plasma, only MCP-1 concentration was signiﬁcant dimin-
ished (p¼0.023) by CS administration. To study in global the answer to the
treatments, we perform a comparison between the effect of each drug to
the levels of each chemokine. This analysis showed us that there were
signiﬁcant differences between the response to the treatment in MCP-1, 6
month after treatment (p¼0.016), and in fractalkine, 9 month after treat-
ment (p¼0.036). In both cases the treatment with chondroitin showed
a diminution of the levels of the chemokines, while paracetamol didn't
affect in the case of MCP-1 or even increased in the case of fractalkine. All
these data show that chemokine attraction of macrophage, T-cell, eosin-
ophil and basophil is reduced with a 6 month treatment with chondroitin.
Conclusions: These results suggest that CS sulphate may represent an
adequate drug to reduce the inﬂammation associated to the OA process.
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LINKING AN ADAMTS5-SPECIFIC THERAPEUTIC MONOCLONAL
ANTIBODY TO A SENSITIVE BIOCHEMICAL MARKER OF TARGET
ENGAGEMENT AND ACTIVITY FOR POTENTIAL APPLICATION AS
A COMPANION DIAGNOSTIC
J. Larkin. GlaxoSmithKline, King of Prussia, PA, USA
Purpose: The goal of co-developing a companion diagnostic alongside
a therapeutic has distinct advantages for drug development and has
recently been suggested by some regulatory agencies to be the preferred
scenario for future approvals. The ability to identify patient subsets most
likely to respond to and beneﬁt from a treatment not only allows for
focused stratiﬁcation and reduced development costs, but also has the
potential to reduce healthcare expenditures through deﬁned treat/non-
treat guidelines. This scenario is especially useful in the context of osteo-
arthritis (OA) where the sheer patient numbers, multifactorial etiology and
unmet need of the patient population dictates an effective stratiﬁed
approach to clinical development and market acceptance.
Methods: The Target: ADAMTS5 - A Disintegrin And Metalloprotease with
ThromboSpondin motifs 5, is a key protease involved in degradation of
cartilage (aggrecan). Activity is upregulated in osteoarthritis1,2 and
inﬂammatory arthritic1,3 diseases leading to impaired joint function and
disability. Genetic loss of function is associated with cartilage protection in
preclinical disease models4-6.
The Therapeutic: A high afﬁnity humanized mAb that speciﬁcally binds
and neutralizes ADAMTS5, engages the target in vivo (cartilage), inhibits
cartilage degradation with extended duration in human OA cartilage
explant studies, and dose dependently modulates circulating ARGS neo-
epitope levels following systemic administration in cynomolgus monkeys,
supporting its potential as an OA disease modifying drug.
Results: The Diagnostic: ARGS Neoepitope - A sensitive immunoassay
capable of quantifying a speciﬁc ‘signature’ of ADAMTS5-mediated
cleavage of aggrecan in serum, plasma, urine and synovial ﬂuid withapplications for patient selection, monitoring response and potentially
efﬁcacy.
Conclusions: The Therapeutic Proﬁle: By delaying structural disease
progression, and stabilizing or improving pain and/or function, it will ﬁll
a large unmet need in joint diseases. As a chronic therapy, the safety proﬁle
will be suitable for long term administration.
580
THE ESSENTIAL OIL OF ERYNGIUM DURIAEI SUBSP. JURESIANUM
INHIBITS IL-1b INDUCED NF-KB AND MAPK ACTIVATION IN HUMAN
CHONDROCYTES
A.T. Ruﬁno 1,2, C. Cavaleiro 3, F. Judas 4, L. Salgueiro 3, M.C. Lopes 1,2,
A.F. Mendes 1,2. 1Ctr. for NeuroSci. and Cell Biology, Coimbra, Portugal;
2 Faculty of Pharmacy, Univ. of Coimbra, Coimbra, Portugal; 3 Lab. of
Pharmacognosy, Faculty of Pharmacy/CEF, Univ. of Coimbra, Coimbra, Portugal;
4Univ. Hosp. of Coimbra and Faculty ofMed., Univ. of Coimbra, Coimbra, Portugal
Purpose: Intracellular signaling pathways, including NF-kB and mitogen-
activated protein kinases (MAPK), modulated by pro-inﬂammatory cyto-
kines, like IL-1b, are known to regulate several genes involved in the
inﬂammatory and catabolic processes that lead to cartilage degradation.
Therefore, these signaling intermediates are considered promising targets
for the development of anti-osteoarthritic drugs with potential disease
modifying properties. Essential oils are complexmixtures of lowmolecular
weight lipophilic molecules with favorable pharmacokinetic properties
that make them especially suited collections for drug screening. Our
previous studies showed that the essential oil isolated from the aerial parts
of Eryngium duriaei subsp. juresianum (M. Laínz) M. Laínz (an Apiaceae
species endemic in the Iberian Peninsula) reduced IL-1b-induced iNOS
expression and nitric oxide production. This work aimed at further eluci-
dating the mechanism of action of that essential oil in human chon-
drocytes, as part of a strategy to identify natural compounds with potential
disease modifying anti-osteoarthritic activity.
Methods: Knee cartilage samples (n¼5) were obtained from multi-organ
donors (23 to 67 years old, mean¼43.2) at the University Hospital of
Coimbrawith approval by the Ethics Committee. After enzymatic digestion,
cells were plated and cultured under non-proliferating conditions. C28/I2
chondrocytic cells were used in some experiments. Cells were serum
starved for 8 to 24 h and treatedwith 3 different concentrations of essential
oil solutions inDMSO for 30minbefore stimulationwith IL-1b,10ng/mL, for
5 or 30 min. The protein levels of total and phosphorylated IkBa, and
phosphorylated p38, JNK and ERK1/2MAPKwere assessed bywestern blot.
Results: In a concentration of 0.02% (v/v), the essential oil signiﬁcantly
decreased IL-1-induced phosphorylation of IkBa, JNK, p38 and ERK1/2 by
78.03.9%, 55.66.7%, 36.40.6% and 24.43.3%, respectively (p<0.001).
Even in a concentration nearly 10 fold lower (0.0025% v/v), the essential oil
still inhibited JNK and p38 phosphorylation by 21.94.48% and 23.16.11%,
respectively (p<0.05).
Conclusions: These results show that the essential oil of E. duriaei subsp.
juresianum reduces both IL-1-induced NF-kB and MAPK activation,
although it is more effective towards inhibition of NF-kB and JNK. Taken
together, the results obtained suggest that this essential oil contains
compound(s) that may present anti-inﬂammatory and anti-catabolic
properties, and thus, potential disease-modifying anti-osteoarthritic
activity. Future work will focus on the fractionation and identiﬁcation of
those compounds followed by further pharmacologic characterization.
Therapy – Surgical & Intraarticular
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10 YEAR SURVIVORSHIP OF THE MEDIAL OXFORD
UNICOMPARTMENTAL KNEE ARTHROPLASTY. A 1000 PATIENT NON-
DESIGNER SERIES - THE EFFECT OF SURGICAL GRADE AND SUPERVISON.
L. Jones, N. Bottomley, H. Pandit, D. Beard, W. Jackson, A. Price. Nufﬁeld
Dept. of Orthopaedics, Rheumatology and Musculoskeletal Sci., Oxford,
United Kingdom
Purpose: The Oxford Unicompartmental Knee Arthroplasty (OUKA) is
a well established treatment option for anteromedial gonarthrosis. The
Abstracts / Osteoarthritis and Cartilage 20 (2012) S54–S296 S291designer series describes ten year survival rates of up to 98%, with no
failures due to polyethylene wear or aseptic loosening of the tibial
component.
However, some smaller non-designer series have failed to replicate these
results. Recent commentaries on registry data have added to the debate
and there is still some confusion as to the true outcome of this procedure. It
has been suggested that both the centre and the individual surgeons
experience are critical is achieving good results. As yet no previous authors
have presented the results of trainees with this prosthesis. Traineesmay be
expected to achieve worse results with a technique that is highly surgeon
dependent.
The aim of this study is to present the survival of a large consecutive cohort
of medial OUKA performed in a specialist centre, bymultiple non-designer
surgeons, with the majority performed by trainees.
Methods: 1085 consecutive primary medial OUKA in 944 patients per-
formed between 1998 and 2008 were identiﬁed at a tertiary centre of
excellence from operative records. In each case the operation was per-
formed by a lower limb arthroplasty surgeon outside the designer team.
Operations performed by both trainee and consultant surgeons were
included. Failure was deﬁned as need for revision of any of the prosthetic
components for any cause and identiﬁed from hospital records, repeat
postal questionnaire to all patients and telephone follow-up of non-
responders. Family Doctor records were consulted in patients who
remained uncontactable. In patients who had died the Family Doctor was
contacted to determine the status of the knee at time of death. Survivor-
ship analysis was by construction of life table and cumulative survival
calculation. Results were stratiﬁed by grade of surgeon and level of
supervision.
Results: 1085 patients with an average age of 67yrs (SD 6.9) at time of
operation were identiﬁed. 681 (62.8%) knees were inserted by over 50
different trainees, 404 (37.2%) by 9 different consultants. At 10 years, 9
(0.83%) patients were lost to follow up and 76 (7%) had died. 46 knees
underwent revision surgery; 34 were revised to total knee arthroplasty
(TKA), 3 had revision of tibial or femoral component, 5 had additional
lateral unicompartmental knee arthroplasty for lateral compartment
progression of arthritis, and 4 underwent bearing change for dislocation or
impingement. The best case survival for the Oxford Medial Uni-
compartmental Knee Arthroplasty was 91% at 10 years. There was no
difference in the survival rates between consultants or registrars (p¼0.47).
If the Consultant was not in theatre at the time of the operation, registrars
achieved a 95% 10 year survival. The presence of the Consultant in theatre
with the trainee reduces survival to 82% at 10 years.
Conclusions: This is the largest single centre non designer series of Oxford
Unicompartmental Knee Arthroplasty ever reported and it demonstrates
excellent survival at 10 years. Over 60 surgeons were involved and there
was no difference in terms of survival between trainee and consultant
surgeons. These excellent results may include well established patient
selection criteria, thorough training programs and close expert supervision
of trainees who are not left to operate unsupervised until thoroughly
competent. Surprisingly, the presence of a consultant supervising a trainee
at the time of the operation led to a reduced 10 year survival. This may be
due to the fact that only fully trained competent registrars are left to
operate unsupervised and more junior and therefore less proﬁcient
trainees are those who are more closely supervised.
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EFFECT OF PREOPERATIVE WEIGHT LOSS ON POSTOPERATIVE
OUTCOMES AFTER HIGH TIBIAL OSTEOTOMY IN PATIENTS WITH
OBESITY, VARUS ALIGNMENT AND MEDIAL COMPARTMENT KNEE OA
A. Boulougouris 1, T.B. Birmingham 1, T.D. Olver 2, K.M. Leitch 1,
P. Lemon 2, J.R. Gifﬁn 1. 1Wolf Orthopaedic Biomechanics Lab., Univ. of
Western Ontario, London, ON, Canada; 2 Exercise Nutrition and Res. Lab.,
Univ. of Western Ontario, London, ON, Canada
Purpose: Varus alignment and obesity are both risk factors for the
progression of medial compartment knee OA and are the targets of various
interventions. The purpose of the present study was to evaluate the effect
of preoperative weight loss on knee-related outcome measures after
medial opening wedge high tibial osteotomy (HTO) for patients with
obesity, varus alignment and medial compartment knee OA. Wehypothesized that decreases in bodyweight preoperatively would result in
better knee-related outcomes 6 months postoperatively.
Methods: A total of 16 patients participated in this prospective cohort
study with matched historical controls. Eight patients completed an 8-
week physiotherapy program (2days/week), supplemented with fat loss
and body composition seminars (1day/week). These patients were
matched to historical controls based on sex, age (within 5 years), BMI
(within 2 points), Kellgren and Lawrence grade in the medial compart-
ment, and Knee Injury and Osteoarthritis Outcome Score (KOOS) Pain
Domain (within 10 points). Outcome measures included the following: 3D
gait analysis (external knee adduction moment and gait speed), all KOOS
domains, the Lower Extremity Functional Scale (LEFS) and the Short Form
12 (SF-12) health status questionnaire. Changes from baseline to 6 months
after surgery were compared between groups using paired t-tests.
Results: The mean weight-loss before surgery was 4.7 kg (95%CI: 2.7, 6.8
kg) for the weight-loss group. Their mean weight-gain 6 months after
surgery was 1.5 kg (95%CI: -0.6, 3.6 kg). At 6 months after surgery, weight
in the preoperative weight-loss group was signiﬁcantly lower than the
controls [mean difference (95%CI): -2.5 kg (-5.4 , -0.3 kg)]. Both groups
improved substantially on all outcomes after surgery. However, there were
no signiﬁcant differences between groups. Between-group mean differ-
ences (95%CI) in change scores were as follows (weight-loss group minus
control group): Peak knee adduction moment, -1.9 Nm (-16.1, 13.8 Nm);
gait speed, 0.07 m/sec (-0.09, 0.22 m/sec); KOOS Pain domain, -2.1 (-21.3,
17.2); LEFS, -3.6 (-19.7, 12.4); SF-12 physical component summary, 1.5 (-7.8,
10.7); SF-12 mental component summary, 1.8 (-7.6, 11.3).
Conclusions: Although the extremes of the 95% conﬁdence intervals do
not exclude potentially clinically important differences between groups,
the present results suggest that obese patients with medial compartment
knee OA who lose weight before medial opening wedge HTO do not have
signiﬁcantly better knee-related outcomes 6 months postoperatively than
similar patients who do not lose weight preoperatively.
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NOVEL CORTICOSTEROID-CONTAINING VISCOSUPPLEMENT
FORMULATION PREVENTS POTENTIAL STEROID-INDUCED ADVERSE
EFFECTS ON CARTILAGE PROTEOGLYCANS
D. Gravett 1, H. Aberman 2, T. Simons 2, P. He 1, H. Panchal 1. 1Carbylan
BioSurgery, Inc, Palo Alto, CA, USA; 2Applied Biological Concepts, Inc, Los
Alamitos, CA, USA
Purpose: Viscosupplements and corticosteroids are commonly used intra-
articularly to treat the pain associated with osteoarthritis of the knee.
Viscosupplements are effective for up to six months but often have a slow
onset (4-6 weeks) for pain relief. Corticosteroids provide rapid pain relief
but often fail to provide long-term relief. A novel viscosupplement,
Hydros-TA, was developed to provide both rapid and long lasting pain
relief for the treatment of pain associated with osteoarthritis. The visco-
supplement comprises a low dose (10 mg) corticosteroid, triamcinolone
acetonide (TA), that is physically trapped within a crosslinked hyaluronic
acid based hydrogel bead suspended in a hyaluronic acid solution
(Hydros). The biocompatibility of this novel viscosupplement was studied
following intra-articular injection into the knee (Stiﬂe) of a goat to
demonstrate that this combination product did not cause adverse effects
on the cartilage and local joint tissue.
Methods: Thirty-six (36) adult goats, 18 castrated males and 18 females
were used to evaluate the local and systemic biocompatibility of the intra-
articular injections of 5.0 ml of Test or Control Material with 6 animals (3
males/3 females) per group. The following 6 treatment groups were used:
(1) Saline, (2) Hydros (viscosupplement with no corticosteroid), (3)
Hydros-TA(10mg), (4) Hydros-TA(40mg), (5) TA(10mg) and (6) TA(40mg).
The TA doses were scaled to animal weight and joint size. The contralateral
knee served as an internal control for each animal. The local biocompati-
bility was evaluated by gross, quantitative and histological analysis of the
joint and synovial ﬂuid at 28 days and 84 days post injection. The Mankin
Scoring system was used to access the effects of the treatment groups on
the joint cartilage. Systemic biocompatibility was evaluated by analysis of
blood chemistry and body weight pre-injection and at the time of sacriﬁce
as well as by histological analysis of the major organs.
